Posttraumatic stress disorder

The Jason Foundation Releases Suicide Prevention Training for First Responders

Retrieved on: 
Tuesday, August 4, 2020
Articles, Psychiatry, Suicide prevention, Abnormal psychology, Emergency medical responders, Jason Foundation, Health, Suicide awareness, Posttraumatic stress disorder, First responder, Suicide attempt

HENDERSONVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --The Jason Foundation, Inc., a nationally recognized leader in youth and young adult suicide awareness and prevention, announced a new training focused on supporting and educating first responders, who are more likely to die by suicide than in the line of duty .

Key Points: 
  • HENDERSONVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --The Jason Foundation, Inc., a nationally recognized leader in youth and young adult suicide awareness and prevention, announced a new training focused on supporting and educating first responders, who are more likely to die by suicide than in the line of duty .
  • Researchers found that elevated levels of PTSD were associated with a higher likelihood of thinking about suicide and/or having a history of suicide attempts.
  • The Jason Foundation's new training is titled, "First Responders Training Module: Addressing Suicide with Youth in the Community and within the Profession."
  • To access the training , visit The Jason Foundation's website and look for First Responders under the How to Get Involved Tab.

COVID-19 Impacts: Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will Accelerate at a CAGR of Over 9% through 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Retrieved on: 
Monday, August 3, 2020
General Health, Pharmaceutical, Health, Mental health, Articles, Psychiatry, Human behavior, Adverse childhood experiences, Anxiety disorders, Stress, Aftermath of war, Posttraumatic stress disorder, Psychological trauma, Post-traumatic

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Growing at a CAGR of over 9%, the market growth will accelerate during the forecast period of 2020-2024.
  • Rising prevalence of PTSD is one of the key factors driving market growth.
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Segmentation
    Post-Traumatic Stress Disorder (PTSD) Therapeutics Market is segmented as below:

CIT Donates Meals to Veteran Families Through Mission 22

Retrieved on: 
Thursday, July 30, 2020
Veterans' affairs, Aftermath of war, Military personnel, Psychiatry, Articles, Military, Military psychiatry, Military sociology, Posttraumatic stress disorder, Veteran

(CIT) today announced that it has donated meals to Mission 22 , an organization supporting the veteran community through treatment programs, memorials and community social impact.

Key Points: 
  • (CIT) today announced that it has donated meals to Mission 22 , an organization supporting the veteran community through treatment programs, memorials and community social impact.
  • Mission 22 supports and serves veterans across the U.S. through various programs that treat veteran issues, such as post-traumatic stress and traumatic brain injury, and create support and awareness around these issues.
  • "CIT is proud to advance causes that are important to our customers," said Alan DeTata, president, Community Association Banking at CIT.
  • Mission 22 supports the veteran community with three main programs; veteran treatment programs, memorials and community social impact.

Sanford Health and TruGenomix announce partnership to commercialize genomic test for PTSD

Retrieved on: 
Thursday, July 23, 2020
Philanthropists, Articles, Psychiatry, Aftermath of war, Military psychiatry, Military medicine, Military personnel, Military sociology, T. Denny Sanford, Posttraumatic stress disorder, Sanford

As part of the strategic partnership, Sanford Health will support TruGenomix by providing its state-of-the-art lab and research capabilities to validate a first-to-market patented blood test for post-traumatic stress disorder (PTSD).

Key Points: 
  • As part of the strategic partnership, Sanford Health will support TruGenomix by providing its state-of-the-art lab and research capabilities to validate a first-to-market patented blood test for post-traumatic stress disorder (PTSD).
  • The genomic test enables earlier identification and improves outcomes for high-risk populations, including veterans, active-duty service members, frontline health care workers, and first responders.
  • "We know genomic medicine will fundamentally change the way we deliver care," said Nathan Peterson, chief of staff, vice president, strategic planning and governance, Sanford Health.
  • Nearly $1 billion in gifts from philanthropist Denny Sanford have transformed how Sanford Health improves the human condition.

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

Retrieved on: 
Thursday, July 16, 2020
Health, Articles, Medicine, Clinical research, Pharmaceutical industry, Clinical pharmacology, Clinical trial, Design of experiments, Posttraumatic stress disorder, Psilocybin

The project, "NeuroPharm Veteran PTSD Research Project (NVPRP)," is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans.

Key Points: 
  • The project, "NeuroPharm Veteran PTSD Research Project (NVPRP)," is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans.
  • In previous work, Leiden University researchers have found that micro doses of psilocybin can stimulate brain function without harming reasoning abilities.
  • The NVPRP will couple NeuroPharm's scientific, academic, and clinical trial expertise with LUMC's leading edge psilocybin research and development.
  • Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

Retrieved on: 
Thursday, July 16, 2020
Health, Articles, Medicine, Clinical research, Pharmaceutical industry, Clinical pharmacology, Clinical trial, Design of experiments, Posttraumatic stress disorder, Psilocybin

The project, "NeuroPharm Veteran PTSD Research Project (NVPRP)," is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans.

Key Points: 
  • The project, "NeuroPharm Veteran PTSD Research Project (NVPRP)," is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans.
  • In previous work, Leiden University researchers have found that micro doses of psilocybin can stimulate brain function without harming reasoning abilities.
  • The NVPRP will couple NeuroPharm's scientific, academic, and clinical trial expertise with LUMC's leading edge psilocybin research and development.
  • Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc.

Retrieved on: 
Tuesday, July 14, 2020
Psychoactive drugs, Articles, Drugs, RTT, Entheogens, Posttraumatic stress disorder, Anxiety disorders, Stress, MDMA, System for Electronic Document Analysis and Retrieval, Psilocybin, Psychological trauma

In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.

Key Points: 
  • In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.
  • About Mydecine Innovations Group Inc.
    Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
  • NeuroPharm was founded by a dedicated group of former military personnel motivated to seek alternative treatments addressing these traumatic disorders experienced by many veterans following active service.
  • For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at www.sedar.com or visit the Company's website at http://www.mydecine.com

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans

Retrieved on: 
Tuesday, July 14, 2020
Psychoactive drugs, Drugs, Receptor agonists, RTT, Entheogens, Psychiatric diagnosis, Pharmaceutical industry, Drug discovery, MDMA, Posttraumatic stress disorder, Psilocybin, Clinical trial

In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.

Key Points: 
  • In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.
  • This inceptive trial will serve as the basis for follow-on trials conducted in Canada and the United States.
  • NeuroPharm boasts extensive established relationships with global military organizations and a distinguished team of inter-disciplinary experts.
  • About Mydecine Innovations Group Inc.
    Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.

R. Rex Parris Serves $50 Million Government Claim on Behalf of Peaceful Black Lives Matter Protestor Severely Injured by Rubber Bullet

Retrieved on: 
Thursday, July 9, 2020
Psychiatry, Los Angeles Police Department, Rubber bullet, Military, Posttraumatic stress disorder, Articles

LOS ANGELES, July 9, 2020 /PRNewswire/ --Attorney R. Rex Parris served a $50 million government claim on behalf of a man who was shot in the back of the head with a rubber bullet by the Los Angeles Police Department (LAPD) during a peaceful Black Lives Matter (BLM) rally.

Key Points: 
  • LOS ANGELES, July 9, 2020 /PRNewswire/ --Attorney R. Rex Parris served a $50 million government claim on behalf of a man who was shot in the back of the head with a rubber bullet by the Los Angeles Police Department (LAPD) during a peaceful Black Lives Matter (BLM) rally.
  • As Randy turned to leave, LAPD fired a barrage of rubber bullets into the crowd, striking Randy in the back of the head.
  • "The term rubber bullets sounds harmless, but they can cause severe injuries when in the wrong hands," Parris added.
  • According to the claim, Randy suffered a traumatic brain injury, a brain hemorrhage, blurred vision, difficulty speaking, PTSD and much more.

Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020

Retrieved on: 
Wednesday, July 8, 2020
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatry, Aftermath of war, Articles, Military, Abnormal psychology, Posttraumatic stress disorder, Psychiatric diagnosis, RTT, Forward-looking statement, Post-Traumatic Stress Disorder, Aptinyx

He is also a Staff Psychiatrist at the VA San Diego Healthcare System.

Key Points: 
  • He is also a Staff Psychiatrist at the VA San Diego Healthcare System.
  • Last month, Aptinyx announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 in patients with PTSD.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.